From: Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Anatomic stage | Prognostic stage | |||
---|---|---|---|---|
HR (95%CI) | P | HR (95%CI) | P | |
IA | Ref | Ref | ||
IB | 0.93 (0.22–3.92) | 0.917 | 2.02 (1.12–3.64) | 0.020 |
IIA | 1.60 (0.95–2.71) | 0.079 | 2.36 (1.45–3.85) | 0.001 |
IIB | 3.02 (1.68–5.42) | < 0.001 | 2.78 (1.31–5.93) | 0.008 |
IIIA | 4.14 (2.35–7.29) | < 0.001 | 4.50 (2.46–8.24) | < 0.001 |
IIIB | – | – | 8.8 (5.33–14.54) | < 0.001 |
IIIC | 8.58 (4.90–15.02) | < 0.001 | – | – |